Supports the body's natural healing response to facilitate new tendon-like tissue growth and changes the course of rotator cuff disease progression...
First pre-sutured fascia allograft designed for hip arthroscopists to help increase surgeon efficiency and reduce operating room time...
Harnessing Hitachi's automated cell culturing and digital technology to overcome intractable diseases...
The wearable ultrasound imaging solution combines the wireless freedom of Clarius ultrasound with the security of the ProbeFix Dynamic, enabling limitless research opportunities of bodies in motion....
VentureBlick, a global venture platform for healthcare innovation, announces the successful closure of its first two deals, securing a total of US$2.6 million for two startups despite a challenging funding environment...
To strengthen the research ecosystem in the country...
Long-term License Agreement Creates Bundled Solutions ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its Elecsys® beta-Amyloid (1-42) CSF II (Abeta42) and Elecsys® Total-Tau CSF assays (tTau) have received U.S. Food and Drug Administration (FDA) 510(k) clearance. The Elecsys AD CSF Abeta42 and tTau assays (used as a tTau/Abeta42 ratio) measure two biomarkers of Alzheimer's pathology, beta-amyloid and tau proteins, in adults ages 55 and older being evaluated for the disease....
Next-generation FDA-cleared medical device brings non-invasive heart and lung disease detection to healthcare professionals at the point of care ...
Australians could benefit from better cancer treatments, new vaccines, depression treatment without medication, and deeper insights into gut health because of new medical research projects funded by the Albanese Government....
